Individualized prophylactic treatment of patients with hemophilia A to improve effectiveness and optimize product consumption on the example of octocog alpha and rurioctocog alpha... von Tolkushin, A. G., Holownia-Voloskova, M. E., Pogudina, N. L.

Volltext

Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus von Tolkushin, A. G., Pogudina, N. L.

Volltext

Clinical and economic studies on pharmacotherapy of malignant neoplasms: the modeling approach von Tolkushin, A. G., Zyryanov, S. K., Pogudina, N. L., Davydovskaya, M. V.

Volltext

Comparative pharmacoeconomic analysis schemes dosage of hormonal stimulation during in vitro fertilization von I. S. Krysanov, V. S. Krysanova, A. G. Tolkushin

Volltext

Cost-effectiveness analysis of the use of mepolizumab in omalizumab-resistant patients with severe asthma von A. G. Tolkushin, V. A. Rogov, D. A. Ivanov, N. L. Pogudina

Volltext

Fixed and separate combination of solifenacin and tamsulosin in urinary disorders associated with benign prostatic hyperplasia: a choice based on price and value comparison von A. G. Tolkushin, A. V. Smirnova, T. N. Ermolaeva, M. V. Davidovsky

Volltext

PUK6 RETROSPECTIVE PHARMACOECONOMIC STUDY OF THE USE OF CYCLOSPORINE A MICROEMULSION (SANDIMMUN® NEORAL®) IN COMPARISON WITH TACROLIMUS (PROGRAF®) FOR IMMUNOSUPPRESSION FOLLOWING K... von Tolkushin, AG, Kulikov, A, Yagudina, Rl, Morozov, A

Volltext

PUK5 RETROSPECTIVE PHARMACOECONOMIC STUDY OF THE USE OF CYCLOSPORINE A MICROEMULSION (SANDIMMUN® NEORAL®) IN COMPARISON WITH CYCLOSPORINE A GENERICS FOR IMMUNOSUPPRESSION FOLLOWING... von Tolkushin, AG, Kulikov, A, Yagudina, Rl, Morozov, A

Volltext

PCN33 ANALYSIS OF DRUG REQUIREMENT FOR TREATMENT ADVANCED HODGKIN'S DISEASE von Tolkushin, AG, Khabriev, RU, Moiseeva, TN, Yagudina, RI

Volltext

PCN21 RETROSPECTIVE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF VARIOUS TREATMENT SCHEMES IN PATIENTS WITH ADVANCED HODGKIN'S DISEASE von Tolkushin, AG, Yagudina, RI, Moiseeva, TN, Khabriev, RU

Volltext

PRS31 SHOULD SALMETEROL/FLUTICASONE PROPIONATE (SAL/FP) BE ADDED TO ROUTINE COPD TREATMENT WITH FENOTEROL/ IPRATROPIUM BROMIDE (FEN/IB)? PHARMACOECONOMIC ASSESSMENT OF COPD TREATME... von Denisov, P, Belevsky, AS, Chuchalin, AG, Tolkushin, A, Yagudina, RI, Kulikov, A, Zinchuk, I

Volltext

PRS32 REGIONAL DIFFERENCES AS A BASIS FOR SENSITIVITY ANALYSIS OF COST-EFFECTIVENESS OF SALMETEROL + FLUTICASONE PROPIONATE (SAL/FP) VS. INHALED CORTICOSTEROIDS (MONO-ICS) von Demko, IV, Tolkushin, A, Yagudina, RI, Kulikov, A, Ogorodova, LM, Chuchalin, AG

Volltext

PRS8 OPTIMA MODEL-BASED COST-UTILITY ANALYSIS OF FIXED COMBINATIONS SALMETEROL/FLUTICASONE VS. BUDESONIDE/FORMOTEROL IN TREATMENT OF ASTHMA IN RUSSIA von Kulikov, A, Yagudina, RI, Tolkushin, A, Demko, IV, Chuchalin, AG

Volltext

PRS15 NEW PHARMACOECONOMIC MODEL OF ASTHMA MAINTENANCE TREATMENT (OPTIMA) IN RUSSIA. TO TREAT OR NOT TO TREAT: MAINTENANCE TREATMENT VS. NO MAINTENANCE TREATMENT von Yagudina, RI, Kulikov, A, Demko, IV, Tolkushin, A, Ogorodova, LM, Chuchalin, AG

Volltext